Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s stock price gapped down prior to trading on Thursday. The stock had previously closed at $14.81, but opened at $10.70. Iovance Biotherapeutics shares last traded at $10.0730, with a volume of 17,767,226 shares changing hands.
Key Headlines Impacting Iovance Biotherapeutics
Here are the key news stories impacting Iovance Biotherapeutics this week:
- Positive Sentiment: Iovance reported a 24.6% objective response rate in 69 patients with non-squamous mNSCLC, consistent with previously disclosed results. The company said the data support a planned supplemental biologics license application for lifileucel in this indication in 2027. Iovance Updated IOV-LUN-202 Results
- Positive Sentiment: Response rates were substantially higher in selected populations: 43.3% for patients with KRAS wild-type disease versus 11.4% for KRAS-mutant disease, while a novel biomarker-enriched subgroup achieved a 59.1% response rate. Iovance plans to begin the registrational-intent POSITIVITY study in November 2026. Iovance Precision TIL Strategy
- Positive Sentiment: The company’s precision TIL strategy could help identify patients most likely to benefit from lifileucel and expand the potential use of its tumor-infiltrating lymphocyte platform beyond advanced melanoma. Positive Lifileucel Data and Precision TIL Strategy
- Neutral Sentiment: Analysts were positioned for a potential earnings beat, while unusually heavy call-option buying indicated some traders were expecting near-term upside. These signals were overshadowed by the clinical-data reaction. Iovance Earnings Expectations
- Negative Sentiment: Investors treated the updated lung-cancer readout as disappointing or less compelling than hoped, sending the stock sharply lower. The overall 24.6% response rate and the pronounced gap between KRAS subgroups raised concerns about the breadth of benefit in the broader mNSCLC population. Iovance Stock Reaction to Lung Cancer Data
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on IOVA shares. Zacks Research raised shares of Iovance Biotherapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 26th. Wells Fargo & Company increased their price objective on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 30th. UBS Group raised their target price on Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a “neutral” rating in a research note on Thursday, August 20th. TD Cowen boosted their price objective on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Finally, The Goldman Sachs Group assumed coverage on shares of Iovance Biotherapeutics in a report on Thursday, September 24th. They issued a “buy” rating and a $15.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.20.
Read Our Latest Stock Analysis on IOVA
Iovance Biotherapeutics Price Performance
The stock has a fifty day moving average price of $11.37 and a 200-day moving average price of $5.82. The company has a market cap of $3.84 billion, a PE ratio of -11.62 and a beta of 0.76.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $99.31 million for the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. Iovance Biotherapeutics’s revenue for the quarter was up 65.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.33) earnings per share. On average, equities analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.45 earnings per share for the current year.
Institutional Investors Weigh In On Iovance Biotherapeutics
Several institutional investors have recently made changes to their positions in the company. Compass Financial Management LLC bought a new position in shares of Iovance Biotherapeutics in the third quarter worth about $37,000. Valley National Advisers Inc. acquired a new position in shares of Iovance Biotherapeutics in the 3rd quarter worth approximately $38,000. Root Financial Partners LLC bought a new stake in Iovance Biotherapeutics during the 3rd quarter worth about $44,000. Provenance Wealth Advisors LLC acquired a new stake in shares of Iovance Biotherapeutics in the 3rd quarter valued at $61,000. Finally, GK Wealth Management LLC bought a new stake in shares of Iovance Biotherapeutics during the third quarter worth approximately $107,000. 77.03% of the stock is currently owned by institutional investors and hedge funds.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.
The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.
Featured Articles
- Five stocks we like better than Iovance Biotherapeutics
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
